be observed in the posterior pituitary lobe in consecutive semithin sections. We also found strong immunoreactivity for SHBG in epithelial cells of the choroid plexus and in a portion of the ependymal cells lining the third ventricle. Mass spectrometry showed that affi nity-purifi ed SHBG from the hypothalamus and choroid plexus is structurally similar to the SHBG identifi ed in the CSF. The multiple localizations of SHBG suggest neurohypophyseal and neuroendocrine functions. The biochemical data suggest that CSF SHBG is of brain rather than blood origin.
that SHBG may bind to a membrane receptor to induce a rapid steroid effects through a G-protein-mediated process [ for review, see 8] . This receptor has been functionally identifi ed in a number of tissues including prostate, testis, breast, liver and brain [8] [9] [10] [11] [12] , its structural features however are still unknown. Recent fi ndings show that SHBG-like proteins secreted from sexually dimorphic structures in the rodent lacrimal and submandibular glands may serve as pheromones [13] .
Little is known about the functional importance of SHBG in the brain. It has been shown that SHBG coupled to estradiol may play a role in the stimulation of oxytocin release in the rat hypothalamus [14] . Intraventricular infusions of SHBG, with and without bound estradiol, facilitate female sexual receptivity in rats while SHBG coupled to dihydrotestosterone blocks this effect [15, 16] , however the effects have not been tested in humans.
The aim of the present study was to assess the distribution of SHBG in the human hypothalamus, choroid plexus and infundibulum. SELDI-TOF mass spectrometry was used to characterize the SHBG molecule expressed in the hypothalamus and to compare its structure with that of serum SHBG, which is known to be expressed in liver, and with SHBG from the cerebrospinal fl uid.
Materials and Methods

Tissue
Human hypothalami, both male (n = 4) and female (n = 3) (mean age 69 8 14 years) with a mean postmortem time ! 30 h, were obtained from the Department of Pathology, FSU-Jena. Experiments were approved by the Ethics Commission, FSU Jena, protocol No. 1065-03/03.
After dissection of the retrochiasmatic portion of the hypothalami, including the mammillary bodies, tissue samples were fi xed by immersion in 4% paraformaldehyde for at least 3 weeks, dehydrated and embedded in paraffi n. Small blocks containing the hypophysial stalk and the median eminence (ME) were dissected and fi xed separately for 1 day in the same fi xative prior to dehydration in ascending ethanol series and embedding in Epon for semithin sectioning. Unfi xed samples of hypothalamus and choroid plexus (n = 3) were dissected and frozen at -80 ° C for biochemical analysis. Cerebrospinal fl uid (CSF) samples were obtained from a departmental collection of control samples [ for details, see 17] . Serum samples were collected from 4 volunteer medical students in the laboratory. Both CSF and serum samples were stored at -80 ° C until biochemical investigation.
Immunocytochemistry
Eight-to 10-m thick serial frontal sections were cut on a Reichert microtome and mounted on glycerol and egg albumincoated glass slides. After removal of the paraffi n with xylene and rehydration, sections were washed in phosphate-buffered saline (PBS) for 2 h followed by treatment with 3% H 2 O 2 and 10% methanol in PBS for 20 min at room temperature (RT), to block endogenous peroxidase activity. After washing in PBS for 1 h, PBS containing 2% normal goat serum was applied for 2 h. After another washing step in PBS, sections were incubated in anti-SHBG overnight at 4 ° C. We used a mouse monoclonal antibody (clone 16D5, for production and characterization see Lewis et al. [18] ) at a dilution of 1: 250 in PBS containing 2% BSA (PBS-BSA). Sections were then washed in PBS and incubated in biotin-conjugated goat antimouse IgG (Vector Laboratories, 1: 150 in PBS-BSA, 2 h at RT). After washing, streptavidin-peroxidase-complex was applied (Vector Laboratories 1: 150 in PBS-BSA, 2 h at RT). The immunoreaction was visualized with freshly prepared 3 ,3 -diaminobenzidine (DAB) and H 2 O 2 in PBS (reagents were obtained from Sigma). After staining, sections were rinsed in distilled water and then dehydrated through an ascending series of ethanol and mounted in Entellan ® (Merck). Immunocytochemical controls were performed with normal goat serum instead of SHBG antibody or with anti-SHBG preabsorbed with synthetic SHBG (100 ng/1 ml antiserum in the fi nal dilution). Serial 1-m-thick semithin sections of the infundibulum and the ME were incubated in 10% sodium methoxide for 2 min, to remove epoxy resin, prior to immersion in PBS. Consecutive sections were stained either for SHBG, as described above, or for oxytocin (OT). Rabbit antiserum to OT (Chemicon AB 911) was used at a dilution of 1: 1,000 in PBS overnight at 4 ° C. Immunoprecipitates were visualized with anti-rabbit IgG 1: 100 for 1 h and rabbit PAP complex 1: 100 in PBS and stained with DAB (all reagents obtained from Sigma, Munich). Stained slides were coverslipped with Entellan ® . Sections were examined with an Olympus BX50 microscope equipped with a digital camera, Olympus DP10 and DP-Soft 3.0 software for microphotography. Anatomical locations of the labeled cells were determined according to the cytoarchitectonic descriptions of Mai et al. [19] .
For control purposes, SHBG antibody was preincubated with the antigen before being applied to the tissue sections. To prevent the cross-reaction of the second antibodies, we omitted the anti-SHBG step in a further control experiment.
Purifi cation of SHBG
For mass spectrometric analysis, human hypothalamic tissues were homogenized mechanically followed by sonication in lysis buffer (0.1 M NaPH 4 pH 7.5 containing 2 m M MgCl 2 (Sigma), 0.5% (v/v), CHAPS (Sigma), 5 m M EDTA (Sigma), 0.02 m M PMSF (Sigma), 0.1 m M leupeptin (Serva), 0.04 l/ml ␤ -mercaptoethanol (Sigma); 5 ml/hypothalamus) and centrifuged at 10,000 g at 3 ° C for 30 min. CSF and the serum samples were centrifuged the same way.
SHBG was purifi ed from the supernatant of the probes using IDM affi nity beads (Chipergen Biosystems, Inc.). 10 l protein A (Sigma) were coupled onto 5 l of the beads. Monoclonal SHBG antibody from mouse (clone 16D5) was incubated on the protein A coupled beads overnight at 4 ° C. Binding capacity of protein A beads is 10 mg/ml IgG in 1 ! PBS. We incubated 500 l of each tissue sample with 10 l protein A-anti-SHBG beads overnight at 4 ° C in an end-over-end mixer. After washing, bound SHBG was eluted with 50% (v/v) acetonitrile in 0.5% (v/v) trifl uoroacetic acid for mass spectrometric analysis. Alternatively, we used polyclonal anti-ABP (653 and 882) raised in rabbit diluted 1: 10 in PBS to elute SHBG from the column. For details of preparation, characterization and specifi city of these antibodies, see Becchis et al. [20] .
SELDI-TOF MS Analysis
Surface-enhanced laser desorption ionization-time of fl ight mass spectrometry (SELDI-TOF) analysis was applied to determine the mass of the bound proteins on the beads. 3 l of the eluted probes were dried on the hydrophobic surface of a H4 chip array after spots were washed with 27% (v/v) acetonitrile in 0.1 M PBS (pH 7.4). We used 2 ! 0.5 l saturated sinapic acid as matrix solution. The chip arrays were analyzed in a ProteinChip Reader (PBS-II; Chipergen Biosystems, Inc.) according to an automated data collection protocol [21] . The instrument was used in positive ion mode. Laser intensity was set at 300 (corresponding to approximately 200 J), using a nitrogen laser, emitting at 337 nm. The digitizer was operated at 250 MHz. 105 transients were averaged over 66% of the target area in a linear sweep to generate each spectrum. Bovine serum albumin and chicken conalbumin were used for external calibration. A deviation exceeding 0.3% from the protein standard was considered signifi cant. We used Chipergen ProteinChip Software 3.1 to data analysis and representation.
PBS instead of tissue extract was applied to the protein A beads coupled to anti-SHBG as a control. We also coupled anti-corticosteroid-binding globulin to the protein A beads to test for the specifi city of binding of the beads complex. The eluted samples were examined in both cases with mass spectrometry as described above. 
Western Blot Analysis
Further samples of eluted protein were reconstituted in 20 l SDS-gel loading buffer (Novagen, Inc.) and boiled for 5 min. Electrophoresis was performed in 4-10% (10 v/w) polyacrylamide gradient gel. Following SDS-PAGE, protein bands were blotted at 400 Vh, 20 ° C onto PVDF membranes (Amersham) in blotting buffer (6.35 g Tris base, 3.62 g glycine, 50 ml methanol in 250 ml distilled water). SHBG was visualized with the ABC method as described above. Rabbit protein-weight marker mix (Novagen) was used as molecular weight references.
Results
Localization of SHBG in the Human Hypothalamus
An overview of the hypothalamic SHBG distribution is given in fi gure 1 . SHBG immunoreactivity could be detected in the perikarya of neurons and ependymal cells and in nerve fi bers. No labeling in the nucleus could be observed. SHBG-immunoreactive (SHBG-IR) cells and fi bers could be found in the magnocellular portions of bed nucleus of the stria terminalis (bnst) ( fi g. 1 A-D), supraoptic nucleus (son) ( fi g. 1 A-F, fi g. 2 A,B), paraventricular nucleus (pvn) ( fi g. 1 D,E, fi g. 2 C, arrowhead) and the perifornical region (fo) ( fi g. 1 E). Single stained cells were found distributed in the medial preoptic area (mpoa) ( fi g. 1 C). SHBG-IR cells were also detected rostral to the pvn in the posterior part of the hypothalamus ( fi g. 1 E), an area that does not correspond to any previously described hypothalamic nucleus. Scattered parvocellular neurons were labeled in the arcuate nucleus (arc) ( fi g. 1 E) and in the pvn ( fi g. 2 C, arrows).
Several immunoreactive fi bers were seen in the infundibulum ( fi g. 1 D,E, fi g. 3 A). Strong arborization of stained fi bers was seen in the ME ( fi g. 1 D, fi g. 2 D) and in the su- prachiasmatic nucleus (SCN), while stained perikarya were only seen in the anterior part of this nucleus ( fi g. 1 D). SHBG-IR cells were also found in a small portion of the ependymal cells, lining the third ventricle ( fi g. 2 C, empty arrowheads) and in most of the epithelial cells of the choroid plexus ( fi g. 2 E, arrowheads). Diffuse SHBG-IR occurred in the neuropil surrounding the third ventricle ( fi g. 2 C); this staining was particularly abundant in the mpoa. Immunostaining was completely absent in the immunocytochemical controls ( fi g. 2 F), indicating that neuronal staining was specifi c for SHBG-IR.
In semithin sections it was possible to identify distinct axonal varicosities in the ME and the infundibulum. Examination of consecutive semithin sections revealed coexistence of SHBG ( fi g. 3 A) with OT ( fi g. 3 B) in identical axons.
Mass Analysis of the SHBG Protein
SELDI-TOF MS analysis identifi ed two protein peaks with different molecular weights which were specifi cally bound to the monoclonal SHBG antibody ( fi g. 4 ). A 49,605 8 6 Da protein peak was identifi ed in the human hypothalamus (HT), CSF, serum and choroid plexus. A 53,909-Da protein was found only in the serum. The control experiments showed only a 48,367-Da protein signal, which is under-represented in the tissue probes. This peak represents an immunoglobulin heavy chain molecule originating from the eluted antibody. The second control experiment proving the specifi city of the protocol showed no protein peaks. 
Western Blot Analysis
Western blot analysis of the purifi ed samples showed bands at two different molecular weights ( fi g. 5 ). A 49-kDa protein band could be found in all tissue probes, while a higher mass protein (around 53 kDa) was only seen in the serum sample. During this process the antibody was not detected in the mass interval presented.
Discussion
Our immunocytochemical fi ndings describe for the fi rst time cellular localization and distribution of SHBG in the human hypothalamus. We found that neuronal perikarya and fi bers were detected in the magnocellular supraoptic nucleus, bed nucleus of the stria terminalis, paraventricular nucleus, perifornical nucleus, arcuate nucleus and in the parvocellular suprachiasmatic nucleus. SHBG-IR fibers were detected throughout the hypothalamic nuclei, in the ME and in the infundibulum. The staining of fi bers in hypothalamus, ME and infundibulum indicates that SHBG is most likely subject to axonal transport to the posterior pituitary lobe. It seems possible that posterior pituitary SHBG is liberated into the systemic circulation along with OT. This is also supported by previous immunoelectron microscopical studies, which show SHBG localized in posterior pituitary secretory vesicles in the rat where it is colocalized with OT [22] . Further, evidence that SHBG in the hypothalamus shows the same characteristics as SHBG from secretory organs such as the testis and mouse lacrimal glands [13, 23] may indicate that it is packaged in synaptic vesicles for extracellular release.
The presence of immunoreactive SHBG in human hypothalamus suggests its involvement in human neurophysiology and possibly neuropathology. Our behavioral data in rats suggest that SHBG is important in control of reproductive behaviors [15, 16] . The observation that estradiol levels control brain SHBG expression [24] also suggests that SHBG is involved in neuroendocrine control. Serum SHBG levels have been shown to increase in patients with Alzheimer's disease [25, 26] . Further studies need to be done to demonstrate whether changes in central SHBG exist in various neurodegenerative ailments.
The distribution of the labeled structures overlaps with the known location of hypothalamic neuropeptide OT. In semithin sections we found coexistence of OT and SHBG in neurohypophysial projections, indicating that both are packaged for transport out of the cell bodies, possibly into the posterior pituitary. We have previously demonstrated the colocalization of SHBG and OT in the rat hypothalamic nuclei and posterior pituitary [6, 27] .
Our SELDI-TOF MS and Western blot studies show two SHBG molecules with different molecular weights. We confi rmed evidence that there is a 53-kDa SHBG protein in blood serum, which is known to originate from hepatocytes [28] . This 53-kDa moiety did not appear in the brain. However, a 49-kDa protein was identical in the hypothalamus and CSF that was also seen in blood serum. Alternatively, spliced and glycosylated variants of SHBG have been demonstrated in various species and in different tissues. The 49-kDa molecular weight could be identifi ed as the SHBG variant, ABP (testosterone-estrogenbinding protein; nomenclature from Swiss-Prot Protein knowledgebase. Englebienne and Doyen [29] showed a distinct SHBG in the serum, with a molecular weight similar to the one we found. They interpreted this as originating from the testis.
We suggest that SHBG in the CSF is rather of brain origin than from blood. A portion of the hypothalamic neuroendocrine cells in humans is likely to express SHBG. Wang et al. [5] demonstrated SHBG production in rat brain using Northern blots while we used RT-PCR to identify production of SHBG in the rat brain [24] . Therefore, it is likely that the SHBG immunoreactivity identifi ed in this study in humans is also produced in the brain.
SHBG, liberated from liquor contacting neurons [30] in the PVN, may enter the CSF, which would account for the observed diffuse immunostaining of the periventricular neuropil. Staining of ependymal and plexus epithelial cells could be due to expression or uptake of the steroidbinding globulin by those cells. It is known that ependymal cells are connected by gap junctions to the periventricular neurons, thus allowing proteins from CSF to enter the surrounding neuropil. The CSF is known to contain signifi cant levels of SHBG [31] , which shows alteration at different physiological and pathological stages such as in Alzheimer's disease [26] .
The extensive distribution of both SHBG-IR neurons and processes suggests multiple functional properties. SHBG may be synthesized and released into blood along with the neurohypophysial hormones. Intrahypothalamic SHBG may be released within the brain where it combines with neurosteroids to control the modulation of mood and behavior.
